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Abstract
Background: The use of ultrasound-guided ablation procedures to treat both
benign and malignant thyroid conditions is gaining increasing interest. This
document has been developed as an international interdisciplinary evidencebased statement with a primary focus on radiofrequency ablation and is
intended to serve as a manual for best practice application of ablation
technologies.
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Methods: A comprehensive literature review was conducted to guide statement development and generation of best practice recommendations. Modified
Delphi method was applied to assess whether statements met consensus
among the entire author panel.
Results: A review of the current state of ultrasound-guided ablation procedures for the treatment of benign and malignant thyroid conditions is presented. Eighteen best practice recommendations in topic areas of preprocedural
evaluation, technique, postprocedural management, efficacy, potential complications, and implementation are provided.
Conclusions: As ultrasound-guided ablation procedures are increasingly utilized in benign and malignant thyroid disease, evidence-based and thoughtful
application of best practices is warranted.
KEYWORDS

international consensus, radiofrequency ablation, thermal ablation, thyroid ablation,
ultrasound-guided ablation

1 | INTRODUCTION
There is growing global interest in ultrasound (US)-guided
ablation procedures for treating benign and malignant thyroid conditions. These procedures are performed by surgeons, radiologists, and endocrinologists, and clinical practice
guidelines have recently been published by several representative professional societies.1–5 Given this multidisciplinary
and international development, there is a pressing need to
identify best clinical practices. The standardization of terminology and reporting criteria has been emphasized as a critical component of this process.6,7
This document has been developed as an interdisciplinary
international statement primarily addressing radiofrequency
ablation (RFA), as this technology has garnered significant
recent interest and is associated with robust literature. Laser
thermal ablation (LTA) and ethanol ablation are wellestablished practices also associated with significant evidence.
Other emerging technologies, including microwave ablation
(MWA), and high-intensity focused ultrasound (HIFU) are
gaining in popularity and warrant evaluation.
With the increasing use of ablation technologies
across a variety of clinical settings, it is important to
define criteria for the candidacy of patients undergoing
these procedures. Such criteria permit assessment of efficacy and promote the judicious use of evolving technologies. This document will address use of ablation
technologies in benign and malignant conditions which
have accrued adequate evidence and received sufficient
attention in the literature; such benign conditions
include nodules with compressive symptoms, cosmetic
disturbance, or autonomously functioning thyroid

nodules. Malignant conditions include recurrent thyroid
malignancy (in the thyroid remnant or in lymph nodes)
and small, low-risk primary thyroid cancers.
Importantly, an established skill set in the performance
of US and US-guided procedures is a prerequisite for the
safe application of US-guided ablation technologies. This
document does not supplant this essential foundational
experience, but rather is intended to serve as a resource to
reduce variation in practice, support delivery of highest
quality care, and promote responsible global dissemination
of these technologies.8 Collectively, the recommendations
provided are intended to offer a manual for best practice
application of ablation technologies.

2 | BACKGROUND
2.1 | Principles of thermal ablation
All thermal ablation techniques are based upon the
destruction of tissue in extreme hyperthermic conditions.
The primary mechanism of cell death is coagulation
necrosis. Below 40 C, cellular damage is reversible without long term effect.9,10 Between 50 and 60 C, irreversible
injury is induced, occurring more rapidly as temperature
increases. Fixed ablation techniques often seek to maintain temperatures in this range for 4–6 min. Beyond
60 C, protein denaturation and cellular membrane disruption result in near immediate tissue necrosis, and is
the premise for the moving shot technique used in
RFA.9,10 Above 100–110 C, tissue vaporization and carbonization occur, creating gas around the electrode that
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may result in insulation, limiting ablation efficacy.11,12
Thermal ablation techniques are differentiated based on
the method used to develop this temperature differential.

2.2 | Radiofrequency ablation
RFA destroys targeted tissue through a combination of
frictional and conduction heat11 generated from highfrequency alternating electric current oscillating between
200 and 1200 kHz.9,13 Frictional heat is created when the
RF waves pass through an electrode, agitating tissue ions
as they try to follow the changes in direction of the alternating current. The result is an increase in the temperature of
the surrounding tissue within a few millimeters of the electrode.9,12,13 Heat conduction from the ablated area yields
slower additional thermal damage to the target tissue and,
eventually, tissue further from the electrode.
Specific to the thyroid, the use of the moving shot
technique minimizes the conductive effect, and thermal
energy is primarily generated via frictional heat.14 In
monopolar mode, the patient becomes part of a closedloop circuit that includes the generator, electrode needle,
and two grounding pads that disperse energy. In bipolar
mode, the current is limited to the needle tip and does
not pass through the patient. RFA-induced tissue damage
depends on both tissue temperature and duration of
heating,10,12 summarized by the equation,9
Coagulation necrosis ¼ energy deposited
 local tissue interaction
 heat lost:
Perfusion-mediated tissue cooling from adjacent
blood flow, known as the heat sink effect, as well as heterogeneity in target tissue (from calcification, fibrosis, or
the presence of fluid) may affect the conduction of electricity and heat, thereby reducing RFA efficacy.12

configuration used for LTA of the thyroid is the Nd:YAG or
Diode laser with an emission wavelength of 1064 nm, combined with planning and simulation software.12 Relative to
other thermal ablation techniques, LTA delivers less total
energy, which may confer greater safety and control in critical areas.3

2.4 | Microwave ablation
Another hyperthermic ablation technique, MWA relies on
generation of an electromagnetic field with wavelengths
between 0.03 and 30 cm and frequency between 900 and
2500 MHz to cause oscillation of polarized ions, specifically
water (H2O).17 This oscillation creates friction and thus
increases the local temperature.18 Because an electromagnetic field is used instead of an electrical current, electrical
conduction is not necessary. As such, the thermal spread is
not as impeded by char or heat sink as with RFA.19 Generally, a needle-like antenna is used to propagate the current,
and multiple antennae may be used together. When multiple antennae are phased, the end result is an exponential
increase in heating. Therefore, MWA offers the ability to
deliver more thermal energy in a shorter time, resulting in
a higher final tissue temperature.18 This reduction in treatment time may be more valuable when treating larger
tumors. Because MWA is especially effective in large
tumors and in tissues that dessicate and then impede electrical currents, MWA is gaining popularity in some organ
systems such as the liver, lungs, and bone.20,21
In the thyroid and compact anatomy of the central
neck, it is possible that these factors represent disadvantages: rapid heating that is less responsive to heat sink
may explain complications described in some early
series.3,22–24 These complications have been avoided in
more recent series, however.22,25,26

2.5 | High-intensity focused ultrasound
2.3 | Laser ablation
LTA is another method of delivering thermal energy that
has been applied to thyroid nodules.3 A laser is a focused
beam of light energy delivered through an optical fiber
into the target tissue.15 Local tissue effects can occur
through various mechanisms, but LTA in the thyroid
results from photon scatter generating heat transfer.12
Energy absorption is nonlinear, temperature-dependent,
and results in unique characteristics that can be manipulated and adjusted to be tumor- and patient-specific.16
There are various laser sources, optical fibers, and wavelengths currently available. The most commonly described

HIFU is a unique noninvasive modality that uses sound
waves as carriers to target a specific lesion or focus. Lowintensity sound waves are nondestructive and form the
basis of applications such as those in physiotherapy, which
stimulate or accelerate natural physiologic response to
injury.27 High-intensity ultrasound, however, transfers sufficient energy to induce coagulative necrosis via thermal and
mechanical injury.28 The thermal effect is achieved by the
conversion of the energy generated by intense tissue vibration into frictional heat. Absorption within a focal target
area creates high temperatures locally, and immediate cell
death occurs once exceeding 55–60  C. At this temperature,
water within tissue vaporizes, and microbubbles begin to
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form. Microbubble expansion and then collapse leads to
mechanical damage to and hemorrhage within nearby cells
through the cavitation process.29 A key component and
challenge of HIFU is the delivery of energy to a small area
without causing damage to intervening and surrounding tissues. This is accomplished by focusing high-intensity waves
from numerous sources outside the body onto the same target, avoiding significant energy accumulation in the propagation path.30
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the American Head and Neck Society – Endocrine
Section (AHNS-ES), Asia Pacific Society of Thyroid Surgery (APTS), Associazione Medici Endocrinologi (AME),
British Association of Endocrine and Thyroid Surgeons
(BAETS), European Thyroid Association (ETA), Italian
Society of Endocrine Surgery Units (SIUEC), Korean
Society of Thyroid Radiology (KSThR), Latin American
Thyroid Society (LATS), and Thyroid Nodules Therapies
Association (TNT) were selected to facilitate collaboration within this international and interdisciplinary group
of societies.

2.6 | Alcohol (ethanol) ablation
Intratumoral administration of ethanol was developed as
a surgical alternative for treating hepatocellular carcinoma and has subsequently been applied across a variety
of benign and malignant pathologies.31–35 As a chemical
ablation technique, ethanol promotes tissue destruction
via two methods. The first is via cellular dehydration,
leading to protein denaturation and the induction of
coagulation necrosis. The second occurs when ethanol
enters local circulation, causing damage to the vascular
endothelium and platelet aggregation with fibrin clot formation, ultimately resulting in vascular thrombosis and
tissue ischemia.36 For this reason, targeting vascularity in
solid and functional nodules has been proposed as a
treatment strategy.37
Because of the variability in diffusion of ethanol from
the site of injection, ablation efficacy can be unpredictable;
ethanol leakage into cervical tissues may induce sharp pain
and late fibrosis. Studies tracking distribution volume of
ethyl alcohol within tumors show off-target leakage limits
the uniform distribution and local retention of the agent,
particularly within larger tumors.38 For these reasons, multiple treatments are often required, and ablation is more
successful in small, encapsulated lesions that provide a
physical barrier to diffusion, maintaining concentration of
ethanol within the interior.39,40 Chemical ablation may also
play an adjuvant role in combination with thermal
therapies.41–43 Ethanol ablation alone is most effective in
the treatment of predominantly cystic nodules and has been
largely abandoned as a treatment method for solid nodules.

3 | METHODS
3.1 | Author panel selection
An author panel was carefully selected to represent surgeons, radiologists and endocrinologists internationally
with expertise in US-guided ablation procedures, as well
as experts in research methodology. Authors representing

3.2 | Literature search and evaluation
approach
A subset of authors (JN, LAO, MR, BCS, GR) conducted
a hand search of literature addressing ablation technologies in the treatment of thyroid conditions and iteratively
generated a structured topic outline to guide manuscript
development. Topics were selected and organized to construct a document that would serve as a manual for best
clinical practice, with topic areas representing phases of
care and areas of information guiding clinical decision-making. Further delineation of topic areas was informed by the
collective experiential knowledge of the group. After iterative development by this subset of authors, the structured
topic outline was shared with the entire author panel for
further refinement.
A comprehensive literature search was conducted to
identify articles addressing ablation procedures in the
treatment of benign and malignant thyroid conditions.
GR and MR identified eight sentinel articles to guide the
search,1,2,12,44–48 which was performed by a medical
librarian. Sentinel articles were selected because they
represented material addressing the clinical application
of ablation technologies in the thyroid gland, including practical information and data on outcomes. Detailed search
strategy and results are listed in Appendix. The medical
librarian-directed search queried Medline via New PubMed
(1946 [inception]–July 31, 2020), Embase.com (1947[inception]–July 31, 2020), Web of Science Core Collection (1900
[inception]–July 31, 2020), Cochrane Library, and
clinicaltrials.gov, using search strategies customized for each
database. The search utilized a combination of controlled
vocabulary and keywords focused on the concepts: “ablation
techniques” and “thyroid gland” (Appendix I: PubMed search strategy). Nonhuman studies were excluded. No filters
for language, study design, or date of publication were used.
To be included, articles had to be focused on thyroid and pertaining to the following ablation technologies: RF, HIFU,
laser, MW, and ethanol. Articles addressing ablation of the
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parathyroid glands or other tissues were excluded, as were
articles without direct relevance for clinical application. Titles
and abstracts were screened independently by GR and
MR. Full-text articles were accessed if the appropriateness of
inclusion could not be readily determined from the abstract
alone. Disagreements were settled by discussion and consensus. After review, a total of 690 articles remained for qualitative synthesis. All articles were provided in full-text form in
an online database for the entire author panel to access. Search results were supplemented with articles of importance
identified by hand search, with all authors invited to
contribute.

3.3 | Proposed statement development
In the next phase, “Best Practice Recommendation” statements were derived. The author groups assigned to each
topic area summarized the literature and critically evaluated
findings in light of their applicability to broad practice. They
generated dialogue among themselves as they analyzed the
data through sharing of draft documents for group review.
Finally, a video conference was held for each author group
to facilitate final discussion and closure.

3.4 | Modified Delphi method
A modified Delphi method was applied to assess whether
statements achieved consensus.49,50 An electronic survey
was distributed to the full panel, and members were
expected to complete their responses without knowing
the responses of others in the group. The results were
then analyzed using a numerical Likert scale with the following anchor points: 1 (strongly disagree); 3 (disagree);
5 (neutral); 7 (agree); and 9 (strongly agree). Statements
were defined as achieving consensus if there was a mean
score of 7.0 or greater and 0–2 outlier responses, or a
mean greater than or equal to 7.0 and 3 outliers with no
outlier value lower than 5 (neutral). Nonconsensus was
the default if these criteria were not met. Outlier responses
were defined as any rating at least 2 Likert points away
from the mean. Statistical analysis was performed utilizing
Stata 15.0 (College Station, TX). Based on the results of this
initial round of assessment, areas of observed nonconsensus
were discussed. When feasible, revised statements were proposed to undergo additional assessment for possible consensus, using the same rating system as above. Two rounds of
surveys were performed, with newly proposed statements
in the second round based on further understanding of panelists' viewpoints. A summary of recommendations can be
found in Table 1.
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4 | P R E P R O C E DUR A L
EVALUATION
4.1 | Benign thyroid nodules
Several disease and patient factors must be considered
when evaluating a patient for RFA and other US-guided
ablation procedures. For benign thyroid nodules, size,
as determined by US measurement, represents the most
objective criterion to determine candidacy. However,
similarly sized nodules cause different degrees of symptoms that vary significantly between patients. Factors
such as body mass index and neck circumference, as
well as precise location within the thyroid, influence
how symptomatic a patient becomes. Isthmus nodules,
for example, tend to cause earlier and more prominent
cosmetic disturbances. For this reason, determining
appropriate size requirements for ablation is challenging. Prior guidelines have suggested a minimum diameter of 20–30 mm with continued growth on US.2,3,51
Given the difficulty in defining objective size criteria,
the presence of compressive symptoms and cosmetic
concerns are considered appropriate clinical indications
to warrant intervention. For instance, a nodule that is
the clear source of clinical symptoms remains an appropriate target for RFA despite limited size. Symptom
score may be assessed on a visual analogue scale of
0 (no symptoms) to 10 (maximal symptoms). Cosmetic
score may be determined by the physician on a scale of
1–4 as has been described previously.2 The Short Form
Health Survey (SF-36) provides generic assessment of
quality of life measures.52 More specifically, the
Thyroid-Related Patient-Reported Outcome (ThyPRO)
is a well-validated 85-item tool for evaluating thyroidrelated quality of life; a recently developed abbreviated
version (ThyPRO-39) is also applicable in this clinical
setting.53
Functional thyroid nodules may be targeted with
RFA.54,55 It should be noted, however, that resolution of
hyperthyroidism is less predictable than after radioactive
iodine (RAI) or extirpative surgery, with reports for success of RFA ranging from 24% to 72%.54,56–58 Because efficacy is associated with nodule volume reduction of 80%
or greater, RFA is best suited for patients with small
(≤3 cm) nodules and contraindications to RAI or surgery.3,59 Scintigraphy is recommended to confirm the
presence of an autonomously functional nodule, as ablation is less effective in toxic multinodular goiter or
Graves' disease.3,60 TSH should be documented prior to
ablation for both functional and nonfunctional nodules;
T3 and free T4 should be measured whenever TSH falls
outside the normal range.

ORLOFF ET AL.
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Summary of recommendations

Recommendation 1

US-guided ablation procedures may be used as a first-line alternative to surgery for patients with benign
thyroid nodules contributing to compressive and/or cosmetic symptoms

Recommendation 2

Although less efficacious than surgery or RAI in normalizing thyroid function, thermal ablation procedures
can be a safe therapeutic alternative in patients with an autonomously functional thyroid nodule and
contraindications to first-line techniques

Recommendation 3a

US-guided ablation procedures may be considered in patients with suitable primary papillary microcarcinoma
who are unfit for surgery or decline surgery or active surveillance

Recommendation 3b

US-guided ablation procedures may be considered in patients with suitable recurrent papillary thyroid
carcinoma who are unfit for surgery or decline surgery or active surveillance

Recommendation 3c

Preprocedural biochemical and imaging assessment aid in determining curative versus palliative treatment
intent for treatment of recurrent papillary thyroid carcinoma

Recommendation 4a

Subjective voice assessment should be undertaken prior to performance of US-guided ablation procedures in
any candidate

Recommendation 4b*

Patients with voice impairment or relevant prior surgical history warrant a laryngeal evaluation and
assessment of vocal fold mobility

Recommendation 4c

Laryngeal exam should be performed prior to ablation on the contralateral side after ipsilateral ablation

Recommendation 5a

Prior to pursuing US-guided ablation procedures, complete radiographic, biochemical, medical, and
symptomatic evaluation should be performed and may be facilitated by completion of a checklist

Recommendation 5b

Prior to pursuing US-guided ablation procedures, discussion should be held with the patient regarding
expected outcome(s) and potential risks

Recommendation 6**

When patient comorbidities and disposition permit, performance of US-guided ablation procedures under
local anesthesia allows for monitoring of periprocedural complications

Recommendation 7

Hydrodissection creates distance between the target lesion and vital structures, thereby minimizing patient
discomfort and reducing unintended thermal spread

Recommendation 8a

In performance of RFA, utilization of the moving shot technique via the transisthmic approach and delivery
of energy only when the needle tip is visualized by US is paramount to effective ablation

Recommendation 8b

The moving shot technique via the transisthmic approach minimizes inadvertent thermal injury to
surrounding critical structures

Recommendation 9

Continuous patient vital sign monitoring is not universally required for all ablation techniques; however,
established guidelines for procedural sedation in adults should be followed if sedation is administered

Recommendation 10

Immediate clinical and ultrasonographic assessment of acute complications following thermal ablation is
required

Recommendation 11a

Subjective voice assessment should be undertaken by the treating physician following ablation in any
candidate

Recommendation 11b

Changes in voice compared with the preoperative status reported by the patient or detected by the physician
require laryngeal evaluation with assessment of vocal cord mobility

Recommendation 12

Careful documentation of both objective and subjective metrics before treatment and during the follow up
period is important to establish treatment effectiveness and to set realistic expectations

Recommendation 13a

Following thermal ablation for benign nodules, primary objective measures of efficacy include
ultrasonographic measurement of volume reduction and preservation or normalization of thyroid function

Recommendation 13b

Patient-reported outcomes, including validated symptom, cosmetic, and quality of life instruments may be
used to determine efficacy

Recommendation 13c

Repeat ablation of a benign nodule can be considered for remnant nodular tissue contributing to unresolved
symptomatic or cosmetic concerns

Recommendation 13d

Retreatment for persistent hyperthyroidism may be performed

Recommendation 14

Following thermal ablation for recurrent malignancy, ultrasonographic determination of tumor volume,
assessment of locoregional disease status, and serum Tg/TgAb are performed to evaluate treatment response

Recommendation 15

In the setting of primary malignancy, sonographic volume reduction or complete resolution of the malignant
lesion, along with long-term assessment of disease progression, are necessary to determine oncologic effect
(Continues)
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(Continued)

Recommendation 16

Assiduous recording of complications resulting from thermal ablation is recommended in order to accurately
inform practitioners and patients about the safety of these procedures

Recommendation 17a

Prior to performing any US-guided thermal ablation procedure, advanced training in and facility with US of
the thyroid and neck are essential

Recommendation 17b

Proficiency with US-guided fine needle aspiration biopsies of thyroid nodules is recommended for performance of
US-guided ablation procedures

Recommendation 17c

The provider should receive specific instruction on the chosen ablation technique, with the opportunity to
practice on a phantom model and observe cases

Recommendation 17d

Optimal practice involves one's initial cases being supervised by a physician experienced in US-guided
ablation procedures

Recommendation 18

Physicians performing US-guided thyroid ablation who do not provide longitudinal patient care should
communicate and facilitate long-term follow-up with a care team specializing in management of nodular
thyroid disease
*Indicates statement did not reach consensus among author voting panel. Seven of 39 voting authors voted
“neutral” or “disagree”
**Indicates statement was borderline for meeting consensus among author voting panel. Three of 39 voting
authors voted “neutral” or “disagree”

In accordance with previous guidelines, a benign cytologic diagnosis must be confirmed via two ultrasound-guided
fine needle aspiration biopsies (FNAB) or core needle biopsies (CNB) prior to ablation of a benign thyroid nodule.2,3,51,61 When ultrasonographic features are highly
specific for benignity, as in spongiform and purely cystic nodules, the second FNAB may be omitted. FNAB is not a prerequisite in functional nodules. Caution should be taken in
ablating nodules with suspicious ultrasound features so as
not to overlook and delay treatment of a malignant lesion.
Retrosternal extension should be carefully assessed with
cross-sectional imaging, and, if significant, renders the
patient unsuitable for ablation.

4.2 | Cytologically indeterminate thyroid
nodules
There is very little literature regarding treatment of cytologically indeterminate nodules with RFA. A primary
objective of surgery in the management of these nodules
is removal and definitive diagnosis. RFA does not facilitate diagnosis to any degree, nor does it remove the nodule. Furthermore, it does not prevent metastasis if a
nodule is indeed malignant, and may confound future
attempts at diagnosis. As such, it is presumed that success in the management of indeterminate nodules would
be radiographic elimination of the target lesion. However, incomplete treatment with RFA has led to tumor
progression in other organ systems and tumor types.62–65
Therefore, management of indeterminate nodules with
RFA is not recommended at this time.66

4.3 | Malignant disease
Surgery is the standard treatment for patients with primary and recurrent well-differentiated thyroid cancer,
although RFA may be an option when surgery is contraindicated or declined. At present, the role of RFA in
the treatment of thyroid malignancy remains an area of
active debate. RFA has been utilized in the setting of
recurrent papillary thyroid carcinoma2,51 and has shown
promising results in papillary thyroid microcarcinoma
(PTMC).67–69 Prior to proceeding with RFA of metastatic
lesions, malignancy should be confirmed via FNAB or
CNB with thyroglobulin washout as needed. The serum
thyroglobulin and thyroglobulin antibody levels are also
determined to assess treatment response during extended
follow-up.
An important distinction in the ablation of recurrent
malignancy is the treatment intent. For a curative strategy, the number of lesions must be limited (≤3 per
patient), confined to the neck, and with maximum tumor
diameter below 1.5–2 cm.48,70,71 If the strategy is palliative, larger tumors can be targeted with RFA when it is
judged that size reduction would reduce symptoms and
improve quality of life due to relationship with critical
structures. In either case, ultrasonographic assessment of
the target nodule(s) is required to determine size, vascularity, and proximity to adjacent structures. In patients
deemed to be at risk for more extensive locoregional or
distant metastatic disease, cross-sectional and/or functional imaging may be required to detect metastatic disease and help define the treatment purpose. These steps
are summarized in Table 2.

ORLOFF ET AL.

TABLE 2
malignancy
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Preablation evaluation of recurrent thyroid

Thyroid carcinoma recurrence
Malignancy confirmation
FNAB
Cytology
Thyroglobulin washout
Core needle biopsya
Recurrence site and size evaluation
Neck ultrasound
Axial imaging (CT or MRI)
Functional images (131I Scan; PET/CT)

(RLN) is not visible but is expected to be present and is
vulnerable to thermal injury (Figure 2). Anterior jugular
veins are sought out and avoided to reduce risk of hematoma formation. Relevant to both benign lesions in the
thyroid gland as well as recurrent malignancy in the central or lateral neck, the vagus nerve must be located in
the carotid sheath. Although not amenable to mapping sonographically, the sympathetic chain is also
considered in its course deep and lateral to the carotid
artery. With lateral neck disease, the operator must be
additionally mindful of the potential locations of the
spinal accessory nerve, brachial plexus, and other
neural structures.

Biochemical evaluation
Thyroglobulin level

4.5 | Voice and laryngeal assessment

Thyroglobulin antibody level
Serum TSH
a

Can be considered if FNAB does not yield sufficient information.

RFA is currently not considered first-line for treatment of primary thyroid cancer. Although mounting data
suggest efficacy, indications for treatment in this setting
are increasingly discussed.72 At present, candidate primary tumors should demonstrate the following characteristics: (1) unifocal microcarcinoma confined to the
thyroid gland, without evidence of extrathyroidal extension or capsular contact, (2) cytologic confirmation of
papillary thyroid cancer without aggressive subtype,
(3) no evidence of metastatic lymphadenopathy, (4) highrisk, ineligible for, or declines surgery.48,71,73

4.4 | Ultrasound evaluation and
considerations
Preprocedural ultrasound is critical in evaluating characteristics of the target lesion in both benign and malignant
disease. Preoperative nodule or tumor dimensions and
volume are established to compare with subsequent
follow-up exams. The proportion of solid and cystic components is assessed to determine the optimal ablation
technique.74,75 Vascularity is additionally observed.
Examples of candidate lesions and corresponding ablative
techniques are shown in Figure 1.
The preoperative ultrasound is also an opportunity to
identify anatomic landmarks for a safe ablation.76 Of particular interest for thyroid nodules and central neck disease is the tracheoesophageal groove, or so-called
“danger triangle,” where the recurrent laryngeal nerve

A voice assessment is required prior to proceeding with
ablation and is a documented component of the physical
examination.77,78 At a minimum, the patient is asked
whether she/he considers her/his voice abnormal or has
noticed changes in pitch, loudness, quality, or endurance.79 Although not routine, additional investigation
with validated instruments80,81 may be considered to
determine the presence and degree of impairment.
Most importantly, voice abnormality requires examination of the larynx to assess vocal fold mobility.
Laryngeal visualization via transnasal or transoral
fiberoptic or mirror laryngoscopy is the gold standard
exam. Adequate assessment of vocal fold mobility may
be obtained using laryngeal ultrasound in select
patients with favorable anatomy.82 Examination of
vocal fold mobility is also indicated if the patient has
undergone prior thyroid or neck surgery.82 Voice is a
poor predictor of objective vocal fold function, and thus
voice assessment alone is not a substitute for laryngeal
examination in this population at higher risk for occult
dysfunction.79

4.6 | Informed consent
Informed consent is another essential component of the
preprocedural process. It is the responsibility of the physician to set clear expectations during and following ablation. Patients may experience some degree of discomfort,
not only in the neck, but in the ears, jaw, teeth, back, or
chest. The risks of RFA are not dissimilar to those of
open surgery and are reviewed in greater detail in the
“Complications” section. A sample informed consent
template for RFA can be found in Figure S1, Supporting
Information.
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(A)

(B)

(C)

(D)

(E)

F I G U R E 1 Ultrasonographic examples and recommended ablative techniques. Sonographic patterns of candidate lesions for ablation.
(A) Examples of benign nodules with primarily solid or spongiform patterns that would be amenable to radiofrequency ablation.
(B) Examples of mixed solid and cystic nodules with a significant cystic component best addressed with a combination of ethanol ablation
(EA) for the cystic portion and RFA for the solid portion. (C) Examples of entirely or nearly entirely cystic nodules likely to be sufficiently
reduced by ethanol ablation (EA) alone. (D) Examples of isolated recurrent papillary thyroid carcinoma in lateral neck lymph nodes,
amenable to RFA. (E) Example of a unifocal papillary thyroid microcarcinoma without adverse features or radiographic evidence of
metastatic disease, amenable to RFA

4.7 | General assessment of procedural
fitness
Evaluation of the patient's overall medical status and constitution is warranted for appropriate preparation, counseling,
and choice of procedural venue. The physician should

inquire about medical conditions and associated medications,
prior surgical history, and pregnancy status. In particular, significant cardiopulmonary comorbidities, especially presence
of a pacemaker, implantable defibrillator, or arrhythmia,
may encourage the physician to pursue treatment under continuous monitoring. Patient factors that warrant
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F I G U R E 2 Position of danger triangle and vagus nerve. The
danger triangle, or anticipated location of the recurrent laryngeal
nerve, is indicated by the red triangle. Note that, on the right side,
this triangle has a longer base moving inferiorly because of the
oblique orientation of the nerve. The vagus nerve (yellow arrow)
appears as a round, hypoechoic structure between the internal
jugular vein (IJV) and common carotid artery (CCA). In some
patients the vagus nerve courses medially within the carotid sheath
in close approximation to the thyroid. Furthermore, the course of
the vagus nerve can be variable with respect to the vessels as the
nerve descends in the neck

consideration for deep sedation instead of local anesthesia
include extreme anxiety, chronic opiate dependence, fibromyalgia, cognitive disabilities, or prior poor tolerance to procedures (i.e., FNAB).83

4.8 | Management of anticoagulation
The introduction of new oral anticoagulants in the past
decade has increased the complexity of periprocedural
anticoagulation management. Optimal strategies must
weigh the procedural bleeding risk, the pharmacokinetics
of the anticoagulant, and the patient's risk for a thromboembolic event. In general, antiplatelet agents such as
aspirin or clopidogrel are stopped 7–10 days before RFA.
Warfarin is held for 5 days preprocedurally. The direct
oral anticoagulants, which include dabigatran,
rivaroxaban, apixaban, and edoxaban, are held for 24–
36 hours.84 All agents can be safely resumed 24 hours
after completing the procedure.
A checklist summarizing the above preprocedural
evaluation steps can be found in Figure S2.
Recommendation 1: US-guided ablation procedures
may be used as a first-line alternative to surgery for
patients with benign thyroid nodules contributing to
compressive and/or cosmetic symptoms.
Recommendation 2: Although less efficacious than
surgery or RAI in normalizing thyroid function,
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thermal ablation procedures can be a safe therapeutic
alternative in patients with an autonomously functional thyroid nodule and contraindications to first-line
techniques.
Recommendation 3a: US-guided ablation procedures
may be considered in patients with suitable primary papillary microcarcinoma who are unfit for surgery or
decline surgery or active surveillance.
Recommendation 3b: US-guided ablation procedures
may be considered in patients with suitable recurrent
papillary thyroid carcinoma who are unfit for surgery or
decline surgery or active surveillance.
Recommendation 3c: Preprocedural biochemical and
imaging assessment aid in determining curative versus
palliative treatment intent for treatment of recurrent papillary thyroid carcinoma.
Recommendation 4a: Subjective voice assessment
should be undertaken prior to performance of US-guided
ablation procedures in any candidate.
Recommendation 4b: Patients with voice impairment
or relevant prior surgical history warrant a laryngeal
evaluation and assessment of vocal fold mobility.
Recommendation 4c*: Laryngeal exam should be performed prior to ablation on the contralateral side after
ipsilateral ablation.
Recommendation 5a: Prior to pursuing US-guided
ablation procedures, complete radiographic, biochemical,
medical, and symptomatic evaluation should be performed and may be facilitated by completion of a checklist, as can be found in Figure S2.
Recommendation 5b: Prior to pursuing US-guided
ablation procedures, discussion should be held with the
patient regarding expected outcome(s) and potential
risks.
Asterisk (*) indicates statement did not reach consensus
among author voting panel. Seven of 39 voting authors
voted “neutral” or “disagree.”

5 | TECHNIQUE
5.1 | Radiofrequency ablation
Although the ensuing description of procedural setup is
specific to the performance of RFA, this component is
similar for LTA, HIFU, and MWA. The differing technical details for these ablation technologies are reviewed
separately below. The venue in which ablation is performed will vary according to the preference of the
proceduralist and anticipated comfort and safety of the
patient.
Prior to procedure check-in, the patient should avoid
a heavy meal and have a companion accompany them to
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FIGURE 3
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Positioning and set up for RFA procedure

and from the appointment. As shown in Figure 3, the
patient lies supine with gentle neck extension, while the
operator is positioned at the head of the table. It is important to understand that the US images will, therefore, be
inverted on the screen. Grounding pads are placed distal
to the neck, usually on both anterior thighs, after confirmation of no metal on the body (e.g., jewelry, piercings,
hearing aids, clothing hooks, or wires), to avoid
conduction-related injuries. The patient's eyes may be
covered to prevent inadvertent injury. The neck skin
should be cleansed and the field draped. For more anxious
patients, a mild sedative (e.g., alprazolam, 0.5–1 mg PO)
may be helpful to maintain relaxation during the procedure.2,3 Measurement of preprocedure and postprocedure
vital signs is recommended. Monitoring of blood pressure,
heart rate, and pulse oximetry may be considered, especially
if administering a sedative. The same degree of monitoring
is not universally required for all ablation procedures and
should be adjusted as indicated by established guidelines
for procedural sedation in adults.85 It is advisable to have
an emergency “crash cart” and oxygen available in the rare
instance where cardiac arrhythmia develops.
Three basic technical components for RFA of thyroid
nodules comprise the procedure: local anesthesia, the transisthmic approach, and the moving-shot technique.86,87 To
prevent pain during RFA, it is important to inject sufficient
local anesthetic (e.g., 1% lidocaine) into the skin puncture
site and around the thyroid capsule.88 Sensory nerves are
present in the skin at the thyroid capsule, but not within
the gland. Local anesthetic is first administered at the
intended site(s) of RFA electrode insertion in the anterior
neck based on baseline ultrasound assessment of trajectory
(ies) required to access the target nodule. Perithyroidal lidocaine injection is then performed. The infiltrated lidocaine
appears as an anechoic band separating the thyroid gland
and overlying sternothyroid muscle. The total amount of

lidocaine that can be safely administered is calculated based
on patient's weight and renal function.89,90
The additional purpose of local anesthetic infiltration
is hydrodissection, which achieves separation of the thyroid from adjacent vulnerable structures and creates a liquid barrier or heat sink. Hydrodissection with lidocaine or
complementary 5% dextrose in water is advantageous
since it does not conduct electricity and provides a thermal
barrier when it surrounds the target organ.91,92 Under
local anesthesia, complications such as voice change and
ptosis can be monitored. In contrast, general anesthesia
may delay the detection of such complications during
ablation.93 Patients are asked to communicate any onset of
neck pain. This usually indicates heating of the thyroid
capsule and thermal propagation outside of the thyroid
gland. Discontinuation of treatment followed by administration of more local anesthetic and/or repositioning of the
RFA electrode is required. Nonverbal patient communication may be utilized to avoid inadvertent injury resulting
from displacement of the electrode with speaking, which
should be avoided while the electrode tip is active.
The transisthmic approach refers to the insertion of
the electrode via the isthmus, in a medial to lateral
direction, for treatment of a nodule in either the right
or left thyroid lobe.94,95 The transisthmic approach
allows the operator to constantly monitor the association between the electrode, target nodule, and vicinity
of the RLN, which is known to be situated in the “danger triangle” , as in Figure 2. The normal isthmic parenchyma between the target nodule and the electrode
insertion site prevents the leakage of hot ablated fluid
to the perithyroidal area, which might otherwise cause
pain or thermal injury. The transisthmic approach
allows the electrode position to remain stable even
when a patient speaks, swallows, or coughs, preventing
possible injury. RFA of actual isthmic nodules may
require a more paramedian approach.
Unlike RFA of other organs such as the liver, where
the active tip of the electrode is fixed to the center of the
target tumor, a moving shot technique is recommended
for treating thyroid nodules. Since thyroid nodules are
often elliptical and exophytic from the thyroid gland,
they are difficult to ablate using a fixed technique,
which may undertreat or overtreat the nodule periphery
and adjacent tissue. Instead, it is advantageous to treat a
thyroid nodule by dividing it into multiple small ablation units which are individually treated.14 The procedure should begin by ablating unit-by-unit, from the
deepest to the most superficial portion of the nodule,
ablating as the electrode tip is withdrawn. Ablation
should be suspended when the electrode moves in a forward direction to be repositioned.96 Power settings are
chosen at the discretion of the operator but start
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conservatively around 45 W and may be increased to
70 W or more according to patient tolerance to increase
ablative efficiency. Since heat and therefore injury can
extend for a distance of 1–3 mm beyond the electrode
tip, advancement of the electrode must take into
account the size of the active tip, level of power, and
proximity to vital structures.75 The location of the electrode tip should be continuously monitored via real time
US during the entirety of the procedure. For ablation of
a benign thyroid nodule, the operator may expect a total
of 15–50 kJ of energy to be applied depending on the nodule size and ablation length.
Vascular ablation techniques have been introduced to
minimize marginal regrowth.75 The artery-first ablation
technique can be used for hypervascular nodules with a
prominent feeding artery.97 Ablating the artery first
reduces edema and the heat-sink effect in hypervascular
tumors, while also limiting risk of hemorrhage, which
can interfere with thermal conduction. Doppler US is
useful for the identification of the nodule's main arterial
supply.
The marginal venous ablation technique is directed at
marginal draining veins which contribute to the heat
sink effect and prevent complete ablation of the margin
of the target nodule.75 This technique is useful for marginal veins at the anterior portion of thyroid nodules,
which have a sufficiently large safety margin for ablation.
This technique may also be helpful in preventing recurrent nodule growth.98
In treating functional nodules and recurrent nodal
disease, a more extensive margin is necessary for complete eradication.88,99 For treatment of recurrent thyroid
cancers, the moving-shot technique should include the
soft tissue surrounding the recurrent tumors.100 The position of tumor relative to normal neck structures including the RLN, esophagus, or trachea must be assessed
prior to ablation.96 The hydrodissection technique is useful for separating a tumor from these critical structures.91,92,101 An electrode with a small active tip
(i.e., 0.38 or 0.5 cm) is effective and safest for treating
small primary and/or recurrent tumors.88

5.2 | Technique/equipment
considerations
As with any procedure, utilization of the appropriate
equipment is necessary to achieve optimal outcomes in
thyroid RFA. The electrodes employed for thyroid RFA
have been specifically designed for this function. Electrodes with varying tip sizes (e.g., 5, 7, and 10 mm) are
available. Choice of tip size should be determined by the
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dimensions of the nodule requiring treatment and the
degree of precision required. Nodules in more high-risk
locations or abutting critical structures call for the use of
smaller electrodes. For larger nodules (>4 cm), use of the
10 mm electrode can be considered in order to reduce
ablation time. The 5 mm electrode is reserved for smaller
nodules and those requiring a high degree of control of
the treatment area. Electrodes with adjustable tip sizes
have been developed, permitting multiple functions in a
single device.102
Currently, monopolar electrodes are used in the
majority of thyroid RFA cases, although bipolar electrodes are also now available. Bipolar probes, in which
current only passes between the electrodes at the tip of
the device, deliver more focused energy. Use of bipolar
electrodes in patients who are pregnant or those with
implanted cardiac electrical devices may be safer.88 Bipolar electrodes have not yet received FDA approval in the
United States but are in clinical use in other geographic
regions, including in Asia and Europe.
Additional innovations have been introduced to further increase the safety profile of thyroid nodule RFA.
Unidirectional ablation electrodes are insulated in a manner to create a more focused, narrower ablation zone and
may be considered for cases in which the ablation target
directly abuts a critical structure.88 Virtual needle tracking systems have also been developed as a means to facilitate monitoring of the electrode tip. These are more
useful for a fixed ablation rather than moving shot
technique,103 although may offer benefit for clinicians
early in their RFA experience.

5.3 | Laser ablation
In LTA, one or multiple 21-gauge introducer needles are
placed 10 mm apart into the thyroid nodule. Optical
fibers of 300 μm diameter are inserted through the sheath
of the needle, then the needle is retracted to allow at least
5 mm of bare fiber to come into direct contact with the
thyroid tissue. After all laser safety checks are completed,
the energy is delivered simultaneously, commonly via
Nd:YAG laser. Typically, a mean power of 2–4 W is
applied for each diode for a total energy of 1200–1800 J
for every illumination. During the laser firing, a highly
echogenic region will develop in real-time from the
heating and vaporization. The fiber(s) can be pulled back
incrementally by 1–1.5 cm to allow additional doses of
energy to be delivered until the entire nodule has been
illuminated. The number of fibers, repeat deliveries after
pullbacks, and total amount of energy used are tailored
to the nodule volume and shape.12,74,104–107
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5.4 | Microwave ablation
The microwave system consists of a generator and an
internally cooled shaft antenna. The generator operates
at a frequency of 2450 MHz, with power up to 100 W.
The antenna is 16-gauge, 10 cm in total length, with a
3-mm active tip. After a 1–2 mm incision is made in the
skin, the antenna is inserted into the isthmus and placed
into the target nodule along its longest axis. The target
nodule is treated in smaller units by using the movingshot technique. The ablation power is commonly set from
20 to 50 W. The procedure is terminated once the entire
nodule is hyperechoic.108–112

5.5 | High-intensity focused ultrasound
The HIFU device consists of an energy generator, a probe
(or transducer), a monitor, and a cooling device. The
probe operates on both an ultrasound image-guiding system and a therapeutic HIFU transducer system, where
the former is placed in the middle of the probe so that
the center of the image captures the focal point of treatment. The probe is positioned on the skin to view the
targeted nodule. Treatment and nontreatment areas are
then defined by the HIFU device, with each ablation site
measuring 7.3–9 mm by 1.8–5 mm. The operator can also
contour the target manually on the monitor in the
sagittal and transverse planes. A HIFU pulse is then
delivered for 4–8 s, followed by a 15–50 s cooling time.
The transducer can emit frequencies of 3 MHz of pulses up
to 125–160 W of power. The first pulse is delivered at the
center of the nodule to allow for initial assessments of white
hyperechoic marks. Each pulse is capable of inducing temperatures between 60 C and 80 C in an ellipsoid shape with
a diameter of 2 mm and length of 9 mm. A laser-based
movement detector interrupts delivery of the US pulse in
the event of neck movement during ablation. Cooling of the
skin is performed by circulating a 10 C liquid through a
balloon at the probe.113–116

5.6 | Ethanol ablation
Like thermal ablation, ethanol ablation is generally performed in an outpatient setting, most commonly for predominantly cystic nodules. The patient is placed supine
in mild neck extension. The skin is prepped and local
anesthetic (1%–2% lidocaine) may be injected at the skin
puncture site.1 Under ultrasound guidance, a single
16–25 G needle is inserted into the center of the cystic
area (gauge depends on the viscosity of cyst content). A
transisthmic approach is recommended to help stabilize
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the position of the needle tip and prevent ethanol leakage
when the patient swallows or speaks. Cyst contents are
aspirated as much as possible, with care taken to keep
the needle tip within the middle of the cyst and avoid
inadvertent puncture of the cyst wall. Sterile saline irrigation can be used to facilitate removal of residual debris,
colloid, and/or dilute high viscosity cyst fluid. Large bore
needles, repeated ethanol injection over an interval
period, or even large pigtail catheters connected to a suction pump have all been used as adjuncts for highly viscous content.117–119
Once all cyst contents have been satisfactorily
removed, an appropriate amount of 95%–99% ethanol is
slowly injected into the cystic space. Although it is recommended that the total amount of ethanol should be
tailored according to the size and internal content of the
lesion and patient tolerance, there is no consensus for an
absolute amount, and larger amounts of up to 50% of
aspirate volume can be considered if re-aspirated after a
short interval.120–124 A minimum retention time of 2 min
was found to be sufficient by Kim et al. for ethanol to
react with the cells.117 If pain is noted during the procedure, the ethanol injection should be stopped and there
should be evaluation for a possible perithyroidal leak.
There is no expert consensus on whether ethanol
should be fully aspirated after instillation. Several studies
have suggested there is no difference in complication or
success rates between groups in which ethanol was
retained or aspirated after injection,125,126 but others have
suggested that complete removal of ethanol after a short
retention time decreases rates of ethanol leakage and
may increase patient satisfaction after the procedure
because of the immediate reduction in the size of the
nodule.117,127 Therefore, the amount of retained ethanol
after injection is left to the operator's discretion.
Percutaneous ethanol ablation may be used to treat
recurrent lymph node disease.128–132 For solid lymph
nodes, a 25-gauge needle is attached to a tuberculin
syringe containing 95%–100% ethanol. Typically, the needle is inserted into the deepest portion of the node and a
small amount of ethanol (0.05–0.1 mL) is injected, causing that portion of the node to become intensely
echogenic. After the “hyperechoic bubble” fades in a few
minutes, the needle is once more visualized and
repositioned within the next zone of the node, injected,
and repeated until the entire lymph node has been adequately treated. Care is taken to inject small amounts of
ethanol in each site to prevent diffusion of ethanol along
the needle track into surrounding cervical soft tissues.
Multiple sessions may be necessary to treat the entire
node. Any residual color perfusion within the node suggests residual vascularity and requires re-treatment. For
predominantly cystic lymph nodes, a technique similar to
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that used for cystic nodules can be used, except that all
residual ethanol is fully aspirated at the end of the
procedure.1
Recommendation 6**: When patient comorbidities
and disposition permit, performance of US-guided ablation procedures under local anesthesia allows for monitoring of periprocedural complications.
Recommendation 7: Hydrodissection creates distance
between the target lesion and vital structures, thereby
minimizing patient discomfort and reducing unintended
thermal spread.
Recommendation 8a: In performance of RFA, utilization of the moving shot technique via the transisthmic
approach and delivery of energy only when the needle tip
is visualized by US is paramount to effective ablation.
Recommendation 8b: The moving shot technique via
the transisthmic approach minimizes inadvertent thermal injury to surrounding critical structures.
Recommendation 9: Continuous patient vital sign
monitoring is not universally required for all ablation
techniques; however, established guidelines for procedural sedation in adults should be followed if sedation is
administered.
Asterisks (**) indicates statement was borderline for
meeting consensus among author voting panel. Three of
39 voting authors voted “neutral” or “disagree.

speaking, breathing, or hemodynamic abnormalities should
be admitted for observation. Postprocedure instructions should
be provided, with specific advice regarding symptoms that
warrant prompt clinical attention. These include severe or
worsening pain, local swelling and erythema, fever, voice
change, difficulty swallowing, or breathing.3
Voice evaluation is a critical component of establishing
procedural safety and monitoring one's own complication
rate. Following completion of treatment, the voice is
re-assessed subjectively by the patient and physician, as was
done preprocedurally.79 Any changes in vocal quality raise
concern for RLN injury, whether via thermal propagation
or compression from nodule expansion or hematoma. In
this scenario, direct visualization of vocal fold motion via
laryngoscopy, either by the operator or a consultative service, must be performed.82 Transcutaneous US also permits
laryngeal assessment, and is perhaps more efficient in the
context of an US-guided ablation. However, adequate visualization is impacted by age and sex, and subtle motion
abnormalities may elude detection on ultrasound.133,134 For
the patient in whom bilateral ablation is being performed,
confirmation of intact vocal fold mobility by direct visualization is recommended between sides in order to prevent
the possible complication of bilateral vocal fold paralysis. A
postprocedural checklist for thyroid ablation can be found
in Figure S3.

6 | POSTPROC EDUR AL
CONSIDERATIONS

6.2 | Extended follow-up

6.1 | Acute postprocedure management
Clinical and ultrasound evaluation should be performed
upon completion of the RFA procedure to assess the area
of ablation and detect potential early adverse effects, as
well as to confirm appropriate response in the target
lesion. The treated area often appears as a mildly hypoechoic and heterogeneous zone, with scattered hyperechoic spots due to tissue dehydration.3 Color Doppler
mapping improves definition of the treated area, which
appears as devoid of vascular signals. If available,
contrast-enhanced US can provide a more accurate
assessment of the loss of small vessel signals and better
depict the incompletely ablated peripheral areas, which
should be treated if safe and indicated.6
Following treatment, application of an ice pack provides
comfort and reduces local edema and discomfort. Antiinflammatory medication (e.g., ibuprofen) may be given orally,
followed by non-NSAID analgesics (e.g., acetaminophen) during the following 24 h. Routine use of steroids and antibiotics
is not indicated. Patients should be observed for 30–60 min
prior to discharge. Any patient with difficulty swallowing,

Following RFA, clinical, radiographic, and biochemical
monitoring are undertaken at regular intervals to assess
treatment response and thyroid function. A suggested
timeline with follow up metrics can be accessed Table S1.
For benign nonfunctional nodules, complete thyroid
function tests as well as thyroid and neck US are performed at follow-up.2–4 At 12 months, the near maximum
expected size reduction has typically been achieved,135
and thyroid function tests are unnecessary beyond this
time. Nodule-related symptom and cosmetic scores
should be documented using consistent validated metrics,
as discussed previously. Long-term follow-up with US is
recommended in all cases, as 5%–24% of treated nodules
have been shown to regrow between 3 and 5 years, and
may require repeat ablation or surgery.136–138 Such decisions are made on the basis of remnant nodular volume
and vascularity on ultrasound, as well as patient satisfaction and symptomatology. Cross-sectional imaging is generally not warranted unless following response to a
nodule with substernal extension.
Because of the potential for more rapid change in hormone status after ablation of an autonomously functional
nodule, thyroid function is evaluated frequently
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postprocedurally, and at least annually thereafter.2,54,139
As with nonfunctional nodules, US is also performed at
each follow-up. Finally, consideration is given to repeating scintigraphy to help assess the degree of functional
response. Repeat ablation or alternative therapeutic interventions may be required for persistent hyperthyroidism.
After ablation of recurrent thyroid malignancy, attention on ultrasonographic follow-up is directed to volume
reduction and intratumoral vascularity to determine
response.70 Thyroglobulin (Tg) and antithyroglobulin
antibody (TgAb) are assessed in conjunction. Crosssectional imaging is optional to further assess treatment
response or to identify new areas of concern. After the
first year, surveillance can be resumed according to the
schedule indicated by tumor status.
It should be noted that the post-treatment nodule
takes on ultrasonographic characteristics that might otherwise be interpreted as concerning, including a hypoechoic background with internal echogenic foci.94,95
While FNAB of ablated nodules does not indicate malignant transformation,140 the interpreting physician must
be aware of these changes in appearance. Ideally, the provider performing the ablation will also continue US surveillance to ensure appropriate interpretation and avoid
undue suspicion and biopsy.
Recommendation 10: Immediate clinical and ultrasonographic assessment of acute complications following
thermal ablation is required.
Recommendation 11a: Subjective voice assessment
should be undertaken by the treating physician following
ablation in any candidate.
Recommendation 11b: Changes in voice compared
with the preoperative status reported by the patient or
detected by the physician require laryngeal evaluation
with assessment of vocal fold mobility.

7 | EFF I CACY/OUTCOMES
7.1 | Measures of success
7.1.1

| Benign disease

RFA may be offered as an alternative to surgical removal
for cytologically benign thyroid nodules in appropriate
patients.2 Whereas surgical success is objectively measured, success after RFA is more likely to be defined by
predetermined expectations agreed upon between the
treating physician and patient.86 Importantly, in establishing metrics of success, it is critical to consider how
these metrics will be understood in the public arena.6
Success of RFA treatment can be determined objectively with volume reduction ratio (VRR) and thyroid

T A B L E 3 Potential outcome measures for ablation in benign
thyroid nodules

Nonfunctioning

Autonomously
functioning

Volume reduction
ratio (VRR)

✓

✓

Serum TSH, free T4a

✓b

✓

Quantitative measures

✓

Radioiodine uptake
(123I) scan
Qualitative measures
Symptom score (0–10)

✓

✓

Cosmetic score (1–4)

✓

✓

ThyPRO/ThyPRO-39

✓

✓

SF-36

✓

✓

a
In the case of a benign nonfunctional nodule, measurement of T3 may also
be necessary to identify/follow isolated T3 toxicosis.
b
While the intent of RFA in benign nonfunctional disease is not to treat
thyroid hormone dysfunction, preservation of pre-existing function should
be assessed.

function studies, which are independent of patient participation.141 However, because the decision to treat benign
nodules is usually based on subjective complaints, it is
meaningful to attempt to quantify the level of preintervention impairment.142 Several validated instruments such as cosmetic questionnaires, quality of life
(QOL) instruments, symptom scores, and even measures
such as the number of treatments and complications may
be utilized.2,143 These measures of effect of therapy are
discussed in greater detail in the “Pre-Procedural Evaluation” section and are included in Table 3.
Like with surgery, successful treatment of functional
nodules involves achievement of a euthyroid state without
antithyroid drugs or thyroid hormone replacement.144 Persistent hyperthyroidism resulting from inadequate treatment is associated with long-term cardiovascular and
skeletal morbidity and even mortality in older adults.145,146
Reduction in antithyroid medication dosing should not be
quantified as treatment success unless a euthyroid status is
achieved and maintained. This may be especially challenging in larger nodules where durable remission is less
likely3,51; in such cases, surgical resection or RAI may be
the more appropriate definitive approach.

7.1.2 |

Malignant disease

Well-differentiated primary thyroid cancers generally
have a favorable prognosis when managed surgically.
Furthermore, in the hands of an experienced surgeon,
complications are rare and outcomes are generally
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excellent. The gold standard for surgical treatment is
complete eradication of tumor. However, in recent
decades, active surveillance has been increasingly
embraced as a safe management strategy for low risk
PTMCs.147 In contrast to surgical resection, successful
outcomes include lack of disease progression and ability
to avoid surgery.
Preliminary studies evaluating the efficacy of thermal ablation techniques for treatment of unifocal PTMC
demonstrate that, with careful patient selection, excellent
volume reduction can be achieved, but complete sonographic disappearance is less consistent. Importantly, volume reduction and complete sonographic disappearance
may not correspond to a complete elimination of carcinoma.148,149 Indeed, among the limited histologic specimens
of PTMC initially managed with RFA described to date, a
majority have demonstrated persistent thyroid carcinoma,
the clinical significance of which is unknown.149 Long-term
outcomes of RFA and other thermal techniques in the treatment of primary thyroid cancers must be better understood
before RFA is routinely offered for management.
While surgical resection is likely to remain the gold
standard for treatment of primary thyroid cancer, RFA
may emerge as a potentially less invasive primary treatment for unifocal, low risk PTMCs, especially in patients
who are poor surgical candidates or who decline surgery.
Under such circumstances, the treatment objective would
not be complete eradication of tumor, but prevention of
disease progression and avoidance of surgery. As with
active surveillance, careful patient selection is critical to
the appropriate application and success of RFA in this
setting.
For locoregionally persistent or recurrent thyroid
cancer, the standard of care remains surgical resection,
although RFA may be indicated for patients at high
surgical risk, who have undergone multiple operations,
or who decline surgery but clinically require
intervention.2,150
Outcome metrics for RFA treatment of malignant
nodules are summarized in Table 4.
Recommendation 12: Careful documentation of both
objective and subjective metrics before treatment and

T A B L E 4 Potential outcome measures for ablation in recurrent
malignancy and PTMC

Sonographic measures

Cytologic/histologic
confirmation

Volume reduction ratio (VRR)

Fine needle aspiration
biopsy (FNAB)

Complete disappearance (CD)

Core needle biopsy

Regional lymph node metastases

Surgical pathology

during the follow-up period is important to establish
treatment effectiveness and to set realistic expectations.
Recommendation 13a: Following thermal ablation
for benign nodules, primary objective measures of efficacy include ultrasonographic measurement of volume
reduction and preservation or normalization of thyroid
function.
Recommendation 13b: Patient-reported outcomes,
including validated symptom, cosmetic, and quality of
life instruments, may be used to determine efficacy.
Recommendation 13c: Repeat ablation of a benign
nodule can be considered for remnant nodular tissue contributing to unresolved symptomatic or cosmetic concerns.
Recommendation 13d: Retreatment for persistent
hyperthyroidism may be performed.
Recommendation 14: Following thermal ablation for
recurrent malignancy, ultrasonographic determination of
tumor volume, assessment of locoregional disease status, and
serum Tg/TgAb are performed to evaluate treatment response.
Recommendation 15: In the setting of primary malignancy, sonographic volume reduction or complete resolution of the malignant lesion, along with long-term
assessment of disease progression, are necessary to determine oncologic effect.

8 | EFFECTIVENESS O F
ABLATION BY TECHNIQUE
8.1 | Radiofrequency ablation
For benign thyroid nodules, RFA appears the most effective US-guided ablation technique for treating solid,
mixed, and spongiform nonfunctioning thyroid nodules.
A meta-analysis of long-term outcomes in benign thyroid
nodules reported a pooled volume reduction of 64.5% at
6 months and 76.9% at 12 months, followed by further
volume reduction of 92.2% at 36 months.151 This was
accompanied by improvement in nodule-related symptoms and cosmesis.138 Compared with surgery for benign
thyroid nodules, RFA is associated with fewer complications, better health-related QOL, and improved preservation of thyroid function.152–154
Data addressing effectiveness of RFA therapy in
treating hyperthyroidism associated with functional nodules are limited and, as of yet, lacks long-term follow-up.
A recent meta-analysis reported TSH normalization in
71.2% after 12 months.99 Patients with smaller nodules
(<12 ml) and volume reduction exceeding 80% are more
likely to be free of symptoms with resolution of hyperthyroidism.59 In comparison with surgery, patients undergoing RFA for autonomously functioning nodules have
lower rates of hypothyroidism and procedure-related
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complications, although significantly fewer achieve thyroid function normalization.152,155
Numerous studies have demonstrated efficacy in the
setting of recurrent/residual thyroid malignancy, with
complete nodular disappearance ranging from 68% to
93%.44,47,70,73,86,156 Recurrence-free survival is similar
between RFA and re-operation, as are rates of posttreatment voice change. Long-term follow-up is limited,
although a single institution study reported 91% of
tumors remained radiographically absent after 5 or more
years.157 Furthermore, RFA may play a role in palliative
symptomatic relief or slowing of local cancer progression,
even where disappearance of disease is not achievable.
As discussed above in detail, RFA in primary thyroid
cancer is a developing application. Data from a large
cohort study of patients with unifocal PTMC reported
complete sonographic disappearance in 88% of tumors,
and average volume reduction of 98.8% after 42 months.
Locoregional progression occurred in 3.6%.68 Several
additional studies demonstrate a comparable degree of
efficacy in low-risk PTMC without evidence of metastatic
disease.67,69,158,159

8.2 | Laser ablation
The use of LTA for the treatment of benign thyroid nodules was developed on experimental and clinical grounds
in 2000,104 and its efficacy has since been confirmed in a
number of studies.160–164 A large, multicenter study of
1534 nodules treated with LA reported volume reduction
of 72%, with significant symptom and cosmetic improvement.165 Conclusive evidence was provided by a multicenter prospective randomized trial of 200 patients that
collectively demonstrated a 57% VRR at 36 months, with
>50% reduction in 67% of cases, paralleled by local symptom improvement in the absence of thyroid function
changes.163
LTA has also been studied in the treatment of autonomous functioning nodules. A prospective randomized
study compared a single treatment of LTA to RAI in
30 patients with autonomous nodules and mild subclinical hyperthyroidism. While nodule size reduced by 44%
in the LTA group, thermal ablation was significantly inferior to RAI in normalizing TSH.166 Similar to RFA,
greater clinical success in treating functional nodules is
seen in patients with smaller nodules in whom substantial (>80%) volume reduction is achieved.167
The utility of LTA for the treatment of PTMC has not
been extensively evaluated. A retrospective study has
reported similar results to RFA, with 94% of lesions
remaining radiographically absent and 5.6% of patients
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demonstrating locoregional metastases over 4 years of
follow-up.168 A systematic review and meta-analysis of
RFA, LTA, and MWA in PTMC reported results from
treatment of 1284 lesions, confirming no significant differences between the three techniques in volume reduction or major complications.169

8.3 | Microwave ablation
MWA for thyroid nodules has been less robustly studied
and has limited long term follow-up. Theoretical advantages of MWA over other thermal ablation techniques
include reduction in treatment time due to larger ablation zone and less heat sink effect.170 However, this may
be coupled with greater risk of pain and adverse outcomes.171 A retrospective study of 222 patients with
447 treated benign thyroid nodules showed a volume
reduction >50% in 82.3% of nodules, and complete resolution of 30.7% of nodules at 6 months post ablation.22
Additional high volume retrospective analyses report volume reduction between 67% and 74% at 6 months, and
80%–89% at 12 months following MWA.171,172 A randomized prospective study demonstrated improved general
and mental health scores at 12 and 24 months, as well as
lower visual analogue pain scores, compared with surgery.173,174 MWA in functional nodules has not been systematically addressed.

8.4 | High-intensity focused ultrasound
HIFU also lacks data from high quality prospective study.
Two systematic reviews of HIFU for benign nonfunctional nodules reported pooled volume reductions of
45%–70% ranging from 3 to 24 months of follow-up.175 A
European multicenter retrospective study demonstrated a
single session of HIFU to result in 30%–35% decrease in
nodule volume.176 As with other thermal ablation techniques, there is an inverse correlation between initial
nodule size and final volume reduction.177,178 Although
limited by selection bias with much larger nodules in the
surgical group, one retrospective study of HIFU compared to thyroid lobectomy for symptomatic benign nodules, showed volume reduction of 51.7% at 6 months post
ablation, shorter hospital stay, lower cost, greater symptom improvement, and less impact on voice in the HIFU
group.179 There is limited data regarding the treatment of
autonomously functioning nodules with HIFU, with single institution comparison of HIFU and RAI showing significantly improved scintigraphic response and resolution
of hyperthyroidism in the RAI group.180
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8.5 | Ethanol ablation
Aspiration followed by ethanol ablation is most appropriate in the ablation of cystic thyroid nodules.181 Expected
volume reduction ranges from 46% to upward of
90%.182–184 Currently, due to the more predictable area of
tissue destruction and ability to treat any solid component, thermal ablation procedures have superseded the
use of ethanol ablation for solid thyroid nodules,3
although ethanol can be combined with the thermal techniques in the treatment of mixed cystic and solid nodules.
Ethanol can be particularly useful in low resources settings, as it is inexpensive and does not require specialized
equipment.
Ethanol ablation has been successfully employed in select
patients with recurrent/persistent well-differentiated thyroid
malignancy to treat low volume metastatic disease in the
neck.130,131,185 Multiple sessions are typically required, with
volume reduction that ranges from 30% to 100%.129 Durability of lesion reduction has been proven in long-term followup exceeding 5 years.185,186

8.6 | Summary and implications of
efficacy data
Overall, there is robust evidence based on prospective
randomized trials and large, multi-institutional studies
with long-term follow-up supporting the efficacy of RFA
and LTA in the treatment of benign, nonfunctional thyroid disease. Their optimal roles in functional nodules
and malignancy continue to evolve, and currently lack
high-volume studies with long term follow-up. The
available data for MWA and HIFU is generally of a
lower level of evidence and primarily based on retrospective or single-center data. Table 5 summarizes the
comparative efficacy of each technique in varied clinical settings, as well as an estimate of complexity as
determined by necessary equipment, level of risk, and
technical expertise.

TABLE 5

The data presented does not represent a systematic
literature review, but rather highlights what is currently
achievable with ablation technology and serves to guide a
physician's choice of modality. For all minimally invasive
techniques, nodule composition, location, and intensity of internal vascularity influence long-term
results.187 Decision making should, therefore, also
take into account the different learning curves, technical requirements, and relative equipment complexities associated with each technology. It is anticipated
that a physician's early thermal ablation practice will
be more conservative in an attempt to avoid complications and that measured results will, in time, match
published data.

9 | P O T E NT I A L C O M P L I C A T IO N S
As with surgery, the proximity of the RLN to the thyroid
and central compartment lymph nodes places it at risk
for injury during ablation procedures. Because studies
examining rates of RLN injury utilizing pre- and postprocedural laryngoscopy are lacking, accurate rates of
RLN injury are difficult to ascertain. A systematic review
and meta-analysis conducted by Chung et al.45 identified
a 1.44% overall rate of transient or permanent voice
change following RFA based on subjective voice assessment. The rate of voice change was higher (7.95%) in the
subset of 176 patients undergoing RFA for recurrent thyroid cancer, primarily in the central compartment. Injection
of cold irrigant in the region of suspected thermal injury
when voice change develops has been proposed as a management strategy for mitigating RLN injury.188 It should be
noted, however, that prior studies have reported hypothermic nerve damage with exposure to cold solutions.189,190
Special consideration is warranted in the patient for
whom bilateral ablation in the thyroid or thyroid bed is
being considered. A high level of scrutiny should be given
to any voice change, and vocal fold examination is necessary prior to proceeding with the contralateral side.

Comparison of efficacy and complexity of ablative techniques
Solid/
predominantly
solid benign nodule

Cystic/
predominantly
cystic benign nodule

Functional
nodule

Primary
malignancy
(PTMC)

Recurrent
malignancy

√√√

√√

√

√√

√

EtOH

N/A

√√√

√

√√

√

Microwave

√√

√

√

√√

√

Laser

√√

√√

√

√√

√

HIFU

√√

N/A

√

N/A

N/A

Radiofrequency

Note: √, √√, or √√√ to designate efficacy of technology for each clinical condition (√√√ is most efficacious). N/A implies insufficient data to assess.
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Edema within the treated nodule is expected transiently
following RFA57; therefore, it may be safer to stage bilateral ablations to avoid consequences of delayed nerve
palsy.
In addition to the RLN, other nerves are at risk of
thermal injury during ablation of the thyroid and/or cervical lymph nodes. Although rare,45 these include the
vagus nerve in the carotid sheath, the sympathetic chain
posterior to the carotid artery, the brachial plexus in the
supraclavicular fossa, and the phrenic nerve on the deep
neck musculature.
Thyroid nodule rupture after RFA has been reported
as the second-most frequent complication occurring after
voice change.45,191,192 Delayed bleeding caused by microvessel leakage leading to nodule enlargement and thyroid
capsule disruption has been proposed as the underlying
mechanism.45,193 Patients typically present with neck
swelling and pain 2–4 weeks following the procedure.
Conservative management is appropriate in the majority
of cases.
Avoidance of hypothyroidism is a primary motivational factor in pursuing RFA over surgery. A multiinstitutional study of 1459 patients with benign nodules
identified treatment-related hypothyroidism in only one
individual, associated with elevated antithyroid antibodies preprocedurally.192 Hypothyroidism following
ablation of an autonomously functional nodule is similarly rare.139 Due to the focused nature of ablation, as
well as the often unilateral approach, postprocedural
hypoparathyroidism has not been reported.
Hematoma is typically the result of inadvertently traversing an anterior jugular or other significant perithyroidal vein, which should be identified by ultrasound
prior to insertion of the needle electrode. Superficial
burns may occur at the grounding pads, although are
more common at the site of electrode contact and during
ablation occurring too close to the skin. Tracheal necrosis
and airway compromise can result from penetration of,
or ablation in close proximity to, the trachea.194
Finally, performing thyroid RFA in either pregnant
women or patients with implantable cardioverter-defibrillators
(ICDs) warrants special deliberation. Monopolar electrodes,
typically employed for thyroid RFA, allow for dispersion of
electrical current. Consequently, experts have expressed concern for possible fetal injury occurring during RFA. The generated electrical waves can also potentially cause interference
with ICD function, representing a lethal threat to patients
who are dependent on an ICD to maintain a normal cardiac
rhythm. No complications in either population have been
reported in the literature; however, at present, data are insufficient. Given the theoretical risk, if one were to perform RFA
in these patient populations, the use of bipolar electrodes,
which minimize electrical spread, would be most appropriate.
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Recommendation 16: Assiduous recording of complications resulting from thermal ablation is recommended
in order to accurately inform practitioners and patients
about the safety of these procedures.

10 | IMPLEMENTATION
RFA of the thyroid is a technique at the intersection of
multiple disciplines, including endocrinology, radiology,
and surgery/otolaryngology. The specialty of the physician, however, is less important than careful patient
selection, familiarity with neck anatomy, and expertise in
cervical US and US-guided procedures. Discussions must
make clear that RFA is one of several management
options for thyroid nodules, with the optimal approach
for an individual patient being a measured consideration
of multiple factors by patient and physician. Because of
the varying training backgrounds among clinicians performing ablation, it is important to make sure that appropriate otolaryngologic backup is immediately available in
the event of certain postprocedural complications including vocal fold paralysis, airway distress, or cervical hematoma. A collaborative multidisciplinary group is thus
optimal for care of the patient undergoing US-guided
ablation procedures.
First and foremost, clinicians planning to incorporate
RFA into their practice must have a comprehensive
understanding of diagnostic and interventional US of the
neck. Ultrasonography is an operator-dependent process
wherein success is determined by the education, motivation, and experience of the examiner. Initial exposure to
ultrasonography often occurs during residency and postgraduate training. Depending on this background, the
ability to perform diagnostic ultrasound may require
more formal accreditation via courses associated with
professional society meetings or continued education
offerings.195 Expertise is not based on training or certification alone, but is acquired through frequent, regular
application of ultrasonography in the clinical setting.196
In addition, proficiency with US-guided FNAB of thyroid nodules is recommended. It is helpful to have specific experience with the transisthmic approach to
biopsies prior to performing an RFA procedure. Attendance at one or more RFA workshops is advisable,
wherein there is opportunity to practice the technique on
phantoms and to observe an experienced practitioner perform the procedure on a patient. Identifying a suitable
proctor before undertaking procedures independently is
also advisable. Literature sources show a lower complication rate among practitioners with 50 or more cases.192
Although there is no certification process to perform
RFA, physicians seeking to responsibly incorporate this
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technique into their practice should consider the training
described as requisite. As there is not a standard minimum experience to establish competency in US-guided
procedures, it may be necessary to define criteria for USguided ablation privileges at an institutional level.
It is recognized that paths to procedural competence
will vary according to specialty-specific training experiences and clinical practice. Overall, the ideal setting in
which RFA is incorporated into practice is one that is
equipped to care for the patient through the diagnostic,
interventional, and surveillance process, providing an
opportunity for follow-up and audit of patients treated.
The performing physician may be a member of an integrated team capable of managing postprocedural clinical,
radiographic, and biochemical expectations via regular communication. Multidisciplinary review of cases undergoing
consideration for US-guided procedures may help to ensure
all stakeholders in the disease management process are
aligned throughout all phases of care.
Recommendation 17a: Prior to performing any USguided thermal ablation procedure, advanced training in
and facility with US of the thyroid and neck are essential.
Recommendation 17b: Proficiency with US-guided fine
needle aspiration biopsies of thyroid nodules is recommended
for performance of US-guided ablation procedures.
Recommendation 17c: The provider should receive
specific instruction on the chosen ablation technique, with
the opportunity to practice on a phantom model and observe
cases.
Recommendation 17d: Optimal practice involves one's
initial cases being supervised by a physician experienced in
US-guided ablation procedures.
Recommendation 18: Physicians performing US-guided
thyroid ablation who do not provide longitudinal patient
care should communicate and facilitate long-term followup with a care team specializing in management of nodular
thyroid disease.

1 1 | SUMMAR Y AND FUTURE
DIRECTIONS
US-guided thermal ablation is increasingly employed as a
safe, minimally invasive alternative to surgery or active
surveillance for both benign and malignant pathologies
of the thyroid. Standardization of practices and reporting
has emerged as an important component of multidisciplinary application of these technologies. This document represents an international collaborative effort to
synthesize best evidence and expert opinion and to serve
as a resource for practical and safe application of thyroid
ablation techniques. While RFA is the dominant focus of
this statement, the clinical framework presented applies
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to other ablation techniques, including LTA, MWA,
HIFU, and ethanol ablation. Future efforts will elucidate
patient- and nodule-specific factors in which one technique should be preferred over others. While all methods
may be appropriate for some patients, not all clinicians
should seek to offer each of these techniques.
Further investigation is required to address areas of
evolving understanding, including:
• Optimal role of thermal ablation in primary malignancy and indeterminate nodules.
• Optimal role of thermal ablation vs. surgery in cytologically benign thyroid nodules.
• The role of thermal ablation in managing metastatic
disease primarily.
• Criteria for determining treatment efficacy and outcomes.
• Prognostic factors for successful ablation and regrowth.
• Timing of additional treatment following an incomplete treatment or regrowth.
• Cost effectiveness for ablation procedures vs. surgical
approaches.
• Patient-related outcome measures for ablation procedures versus surgical approaches.
• Comparative efficacy, safety, and ideal applications of
varied thermal ablation techniques.
• Long-term efficacy in all clinical applications.
• Minimum expectations for training and experience
prior to offering thermal ablation.
• Disseminating and securing global availability of ablation technologies.
As interest in ablation technologies grows among practitioners and patients, appropriate application of evidencebased principles and techniques should remain a priority.
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